UY35126A - Ojo es alfa - Google Patents

Ojo es alfa

Info

Publication number
UY35126A
UY35126A UY0001035126A UY35126A UY35126A UY 35126 A UY35126 A UY 35126A UY 0001035126 A UY0001035126 A UY 0001035126A UY 35126 A UY35126 A UY 35126A UY 35126 A UY35126 A UY 35126A
Authority
UY
Uruguay
Prior art keywords
alpha
eye
tyk
ifna
alfa
Prior art date
Application number
UY0001035126A
Other languages
English (en)
Inventor
Ryan M Moslin
David S Weinstein
Stephen T Wrobleski
John S Tokarski
Kumar Amit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY35126A publication Critical patent/UY35126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos que tienen la siguiente Fórmula I, o un estereoisómero o una sal de aquellos aceptable desde el punto de vista farmacéutico, en donde R1, R2, R3, R4 y R5 son como se definen en la presente, son útiles para la modulación de IL-12, IL-23 y/ o IFNa (ALFA) que actúan en Tyk-2 para generar la inhibición de la transducción de señal.
UY0001035126A 2012-11-08 2013-11-07 Ojo es alfa UY35126A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08

Publications (1)

Publication Number Publication Date
UY35126A true UY35126A (es) 2014-05-30

Family

ID=49876960

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035126A UY35126A (es) 2012-11-08 2013-11-07 Ojo es alfa

Country Status (38)

Country Link
US (6) US9505748B2 (es)
EP (3) EP2922846B1 (es)
JP (3) JP6407159B2 (es)
KR (1) KR102195194B1 (es)
CN (1) CN104884454B (es)
AR (1) AR094452A1 (es)
AU (4) AU2013341186B2 (es)
BR (1) BR112015010102B1 (es)
CA (1) CA2890981C (es)
CL (1) CL2015001231A1 (es)
CY (2) CY1121188T1 (es)
DK (2) DK2922846T3 (es)
EA (1) EA028814B1 (es)
ES (2) ES2914793T3 (es)
FI (1) FIC20230028I1 (es)
FR (1) FR23C1030I1 (es)
HK (1) HK1215255A1 (es)
HR (2) HRP20220766T1 (es)
HU (3) HUE059409T2 (es)
IL (1) IL238610A0 (es)
LT (3) LT3495358T (es)
MA (1) MA38072A1 (es)
MX (2) MX2015005731A (es)
MY (2) MY175448A (es)
NL (1) NL301238I2 (es)
NZ (1) NZ708859A (es)
PE (1) PE20150944A1 (es)
PH (1) PH12015501004B1 (es)
PL (2) PL3495358T3 (es)
PT (2) PT2922846T (es)
RS (2) RS58187B1 (es)
SG (3) SG10201706985UA (es)
SI (2) SI3495358T1 (es)
TR (1) TR201820824T4 (es)
TW (1) TWI605041B (es)
UY (1) UY35126A (es)
WO (1) WO2014074661A1 (es)
ZA (1) ZA201504052B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175448A (en) * 2012-11-08 2020-06-29 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifna responses
EA028052B1 (ru) 2012-11-08 2017-10-31 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2015123453A1 (en) * 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
PT3757097T (pt) * 2015-11-26 2022-06-20 Novartis Ag Derivados de diamino piridina
CA3039202A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MA48602A (fr) 2016-12-13 2020-03-18 Bristol Myers Squibb Co Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AR111233A1 (es) 2017-03-08 2019-06-19 Nimbus Lakshmi Inc Inhibidores de tyk2, usos y métodos para la producción de los mismos
EP3601268B1 (en) * 2017-03-30 2021-03-17 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
SG11202004592TA (en) 2017-11-21 2020-06-29 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
AU2019234574A1 (en) 2018-03-12 2020-09-03 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
ES2944733T3 (es) * 2018-03-22 2023-06-23 Bristol Myers Squibb Co Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa
WO2019232138A1 (en) 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
JP2022505987A (ja) * 2018-10-22 2022-01-14 エスカー セラピューティクス，インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
BR112021007861A2 (pt) * 2018-10-30 2021-08-03 Bristol-Myers Squibb Pharma Company compostos heterocíclicos substituídos por amida
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
JP2022518505A (ja) 2019-01-23 2022-03-15 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR20210119426A (ko) * 2019-01-28 2021-10-05 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
SG11202108162SA (en) * 2019-01-30 2021-08-30 Bristol Myers Squibb Co Amide-disubstituted pyridine or pyridazine compounds
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
CA3138473A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
JP2022536489A (ja) 2019-06-12 2022-08-17 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態
CN114364665A (zh) * 2019-07-16 2022-04-15 百时美施贵宝公司 调节白介素的前药
US20220281842A1 (en) * 2019-08-01 2022-09-08 Integral Biosciences Pvt. Ltd. Heterocyclic compounds as kinase inhibitor and uses thereof
CA3150108A1 (en) 2019-09-13 2021-03-18 Neelu Kaila HPK1 ANTAGONISTS AND THEIR USES
EP4031109A1 (en) * 2019-09-18 2022-07-27 Bristol-Myers Squibb Company Extended release dosage forms for tyk2 inhibitors
US20230039086A1 (en) * 2019-12-17 2023-02-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Bms-986165 crystal form, preparation method therefor and use thereof
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
BR112022017440A2 (pt) * 2020-03-11 2022-10-18 Beijing Innocare Pharma Tech Co Ltd Compostos heterocíclicos para inibir atividades de tyk2
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
KR20230004771A (ko) * 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113773262A (zh) * 2020-06-09 2021-12-10 江苏先声药业有限公司 哒嗪类化合物
CN115667246A (zh) * 2020-07-24 2023-01-31 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
MX2023003194A (es) 2020-09-18 2023-04-13 Bristol Myers Squibb Co Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
US20240059671A1 (en) * 2020-11-12 2024-02-22 Cullgen (Shanghai), Inc. Tyrosine kinase 2 (tyk2) degradation compounds and methods of use
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
WO2022121868A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
WO2022165141A1 (en) 2021-01-29 2022-08-04 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
JP2024505571A (ja) 2021-02-02 2024-02-06 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
JP2024509192A (ja) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
WO2022193499A1 (en) * 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20230163469A (ko) 2021-03-29 2023-11-30 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
WO2022206705A1 (zh) * 2021-03-30 2022-10-06 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
CN115197196A (zh) * 2021-04-06 2022-10-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
WO2022233286A1 (zh) 2021-05-04 2022-11-10 上海喆邺生物科技有限公司 一类含氮杂环吡啶类化合物
EP4337656A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240008339A (ko) 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
JP2024518792A (ja) 2021-05-14 2024-05-02 ブリストル－マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
US11866414B2 (en) * 2021-05-14 2024-01-09 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
IL309572A (en) * 2021-06-22 2024-02-01 Medshine Discovery Inc Sulfoximine compound and its uses
WO2023284869A1 (zh) * 2021-07-15 2023-01-19 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
KR20240050380A (ko) 2021-08-20 2024-04-18 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의결정 형태
WO2023027948A1 (en) * 2021-08-21 2023-03-02 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
AU2022350509A1 (en) 2021-09-23 2024-04-04 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023055901A2 (en) 2021-09-30 2023-04-06 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023076515A1 (en) 2021-10-28 2023-05-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
WO2023102085A1 (en) 2021-12-01 2023-06-08 Teva Czech Industries S.R.O. Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
WO2023109954A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2023231997A1 (zh) * 2022-05-31 2023-12-07 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024102683A1 (en) 2022-11-08 2024-05-16 Bristol-Myers Squibb Company Substituted heterocyclic compounds
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184376B1 (en) * 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
WO2000076980A1 (fr) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques azotes ou leurs sels
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
WO2004007682A2 (en) 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
RU2012141536A (ru) * 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
KR20130051507A (ko) 2010-09-15 2013-05-20 에프. 호프만-라 로슈 아게 아자벤조티아졸 화합물, 조성물 및 사용 방법
WO2012066061A1 (en) 2010-11-19 2012-05-24 F. Hoffmann-La Roche Ag Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
US9145414B2 (en) * 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
AR089682A1 (es) * 2012-01-10 2014-09-10 Hoffmann La Roche Compuestos de piridazina-amida
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
JP2015534959A (ja) * 2012-10-19 2015-12-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｓｙｋの阻害剤
MY175448A (en) * 2012-11-08 2020-06-29 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifna responses
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
EA028052B1 (ru) 2012-11-08 2017-10-31 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
EP3601268B1 (en) * 2017-03-30 2021-03-17 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Also Published As

Publication number Publication date
HUS2300025I1 (hu) 2023-08-28
AU2020203967B2 (en) 2020-10-22
US20180265504A1 (en) 2018-09-20
SI3495358T1 (sl) 2022-06-30
HRP20220766T1 (hr) 2022-09-16
AU2013341186B2 (en) 2017-03-30
PT3495358T (pt) 2022-06-02
ZA201504052B (en) 2017-11-29
LT2922846T (lt) 2018-12-10
US11021475B2 (en) 2021-06-01
AU2020203967A1 (en) 2020-07-16
PH12015501004A1 (en) 2015-07-27
MY194668A (en) 2022-12-12
CY2023017I2 (el) 2024-02-16
JP2020002157A (ja) 2020-01-09
EP3495358B8 (en) 2022-06-08
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
KR20150081339A (ko) 2015-07-13
EP3495358B1 (en) 2022-04-27
CN104884454A (zh) 2015-09-02
CY2023017I1 (el) 2023-11-15
DK2922846T3 (en) 2019-01-21
SG10201706897TA (en) 2017-09-28
MA38072A1 (fr) 2016-07-29
EP2922846A1 (en) 2015-09-30
CA2890981C (en) 2022-07-05
AU2018267545A1 (en) 2018-12-13
NZ708859A (en) 2018-11-30
LTPA2023523I1 (es) 2023-09-11
PL3495358T3 (pl) 2022-06-27
EA028814B1 (ru) 2018-01-31
TR201820824T4 (tr) 2019-01-21
FR23C1030I1 (fr) 2023-10-13
CL2015001231A1 (es) 2015-08-28
US10000480B2 (en) 2018-06-19
AU2017201076A1 (en) 2017-03-09
MX2020003156A (es) 2020-07-29
WO2014074661A1 (en) 2014-05-15
FIC20230028I1 (fi) 2023-08-28
ES2702148T3 (es) 2019-02-27
JP6585231B2 (ja) 2019-10-02
PT2922846T (pt) 2018-12-19
MY175448A (en) 2020-06-29
CN104884454B (zh) 2017-11-28
US20170022192A1 (en) 2017-01-26
AU2013341186A1 (en) 2015-07-02
HUE059409T2 (hu) 2022-11-28
MX2015005731A (es) 2015-09-16
DK3495358T3 (da) 2022-05-23
RS58187B1 (sr) 2019-03-29
EP2922846B1 (en) 2018-10-03
HRP20181937T1 (hr) 2019-01-25
IL238610A0 (en) 2015-06-30
EP3495358A1 (en) 2019-06-12
ES2914793T3 (es) 2022-06-16
NL301238I2 (nl) 2023-10-04
EP4071144A1 (en) 2022-10-12
USRE47929E1 (en) 2020-04-07
HUE041750T2 (hu) 2019-05-28
KR102195194B1 (ko) 2020-12-24
CA2890981A1 (en) 2014-05-15
AU2018267545B2 (en) 2020-04-02
JP2016506369A (ja) 2016-03-03
AR094452A1 (es) 2015-08-05
US9505748B2 (en) 2016-11-29
US20220356180A1 (en) 2022-11-10
SG11201503399XA (en) 2015-05-28
PL2922846T3 (pl) 2019-03-29
PE20150944A1 (es) 2015-06-20
LT3495358T (lt) 2022-05-25
JP2018154636A (ja) 2018-10-04
SG10201706985UA (en) 2017-10-30
TW201422593A (zh) 2014-06-16
HK1215255A1 (zh) 2016-08-19
US20150299183A1 (en) 2015-10-22
US10526321B2 (en) 2020-01-07
BR112015010102A2 (pt) 2017-07-11
JP6407159B2 (ja) 2018-10-17
PH12015501004B1 (en) 2015-07-27
US20200071315A1 (en) 2020-03-05
BR112015010102B1 (pt) 2022-02-08
SI2922846T1 (sl) 2019-04-30
CY1121188T1 (el) 2020-05-29
EA201590917A1 (ru) 2015-09-30
AU2017201076B2 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
UY35126A (es) Ojo es alfa
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
CL2020001338A1 (es) Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona.
EA201590913A1 (ru) АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
PH12015501005A1 (en) Heteroaryl substituted pyridil compounds useful as kinase modulators
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY35333A (es) Compuestos de azabencimidazol
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CO6592042A2 (es) Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
RS54730B1 (sr) Inhibitori beta sekretaze
EA201690911A1 (ru) Соединения диметилбензойной кислоты
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
EA201690894A1 (ru) Феноксиэтилы
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
EA201592183A1 (ru) Ингибиторы bace
AR095097A1 (es) Compuestos de fenoxietoxi
MA39866A (fr) Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.